<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="201869">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00461812</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00001154</org_study_id>
    <nct_id>NCT00461812</nct_id>
  </id_info>
  <brief_title>A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma</brief_title>
  <official_title>A Single-Blind, Randomized, Positive-Controlled Study to Compare Monotherapy With an Inhaled Corticosteroid (Mometasone) to Combination Therapy With an Inhaled Corticosteroid + a Long-Acting Bronchodilator (Advair) in Patients With Milder Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research hypothesis for the proposed study asks the question, can Asmanex® demonstrate
      comparable anti-inflammatory therapeutic efficacy to the combination product, Advair® in
      control of mild persistent asthma?

      The purpose is to demonstrate that the anti-inflammatory protection afforded by monotherapy
      with an inhaled steroid (Asmanex®) is comparable to combination therapy with Advair® 100/50,
      when measured by this standard methodology (methacholine bronchoprovocation) in subjects
      with mild persistent asthma.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2007</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind</masking>
  </study_design_info>
  <enrollment>45</enrollment>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone or Advair</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subjects 18 to 65 years of age

          -  a &gt;2 year history of asthma

          -  FEV1 &gt; 80% for subjects currently using Advair®.

        Exclusion Criteria:

          -  severe asthma

          -  current smokers

          -  pregnant or breast-feeding women

          -  other chronic significant illnesses
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter S Creticos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arouna P Khattignavong, MD</last_name>
    <phone>410-550-2184</phone>
    <email>akhatti1@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan L Balcer Whaley, MPH</last_name>
    <phone>410-550-2122</phone>
    <email>swhaley1@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins Asthma and Allergy Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter S Creticos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <lastchanged_date>April 16, 2007</lastchanged_date>
  <firstreceived_date>April 16, 2007</firstreceived_date>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
